Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-arginine + acetylsalicylic acid is a combination drug that merges the properties of two well-known molecules. L-arginine is an amino acid that serves as a precursor to nitric oxide, leading to vasodilation and improved endothelial function. Acetylsalicylic acid (aspirin) is a nonsteroidal anti-inflammatory drug (NSAID) with antiplatelet and anti-inflammatory effects due to its irreversible inhibition of cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin and thromboxane synthesis. The combination aims for synergistic cardiovascular benefits by enhancing blood flow through nitric oxide-mediated vasodilation while simultaneously reducing inflammation and preventing platelet aggregation via aspirin’s action[1][2]. Preclinical studies suggest that co-administration may protect against aspirin-induced endothelial dysfunction by increasing dilator prostanoids[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on L-arginine + acetylsalicylic acid.